Needham initiated coverage on Axsome Therapeutics, highlighting its diverse CNS portfolio. The analyst predicts an 8-10x risk-adjusted topline growth in five years, driven by marketed drugs Auvelity and Sunosi, along with promising late-stage assets.
Read more